Search

Boulder-based miRagen Therapeutics, the biopharmaceuticals firm led by William Marshall developing microRNA-based therapeutics, said Tuesday that it has raised $41M in a Series C funding round. The funding was co-led by MRL Ventures, the venture arm of Merck, along with JAFCO Co., and also included Brace Pharma Capital, MP Healthcare Venture Management, Atlas Venture, Boulder Ventures, Remeditex Ventures, Amgen Ventures and others. Joshua Resnick, M.D., president of MRL Ventures, will join the company's board with the funding.
posted on Wednesday, November 11, 2015 (Link to more information)

Related companies:
Miragen Therapeutics

Related stories:
> miRagen Therapeutics Raises $40M, Goes Public In Reverse Merger
> miRagen Therapeutics Finds $20M
> miRagen Therapeutics In Strategic, Funding Deal With Servier
> Miragen Therapeutics Gains $3.0M More
> Miragen Therapeutics Raises $8M
> miRagen Therapeutics Gets $4M

---

Techrockies.com Home